Amide Lab at the Engine Accelerator in Cambridge, MA (courtesy Amide)

MIT spin­out aims to im­prove man­u­fac­tur­ing of pep­tides 

Amide Tech­nolo­gies is now mar­ket­ing its pep­tide man­u­fac­tur­ing tech­nol­o­gy at a time when pep­tide-based ther­a­pies such as No­vo Nordisk’s We­govy and Eli Lil­ly’s Moun­jaro are in high de­mand.

The Cam­bridge, MA start­up, which was spun out of the Mass­a­chu­setts In­sti­tute of Tech­nol­o­gy in 2016, de­vel­oped a tech­nol­o­gy that more quick­ly syn­the­sizes long chains of amino acids in­to pep­tides.

CEO Mark Si­mon said in an in­ter­view with End­points News that Amide’s tech could help ease the sup­ply crunch for GLP-1 drugs be­cause the com­pa­ny man­u­fac­tures pep­tides faster than tra­di­tion­al meth­ods. Lil­ly and No­vo have both re­port­ed sev­er­al man­u­fac­tur­ing road­blocks try­ing to meet the de­mand for their GLP-1 drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.